Beijing GeneCradle Technology Co., Ltd. (hereinafter referred to as "GeneCradle") was successfully selected and awarded as the "National Intellectual Property Advantage Enterprise" in 2023. This award is a high recognition given by the state to the company's intellectual property management work.
"National Intellectual Property Advantage Enterprises" refers to enterprises that belong to the key industrial fields of national and regional development, can undertake major and key industrial development projects of the country and region, have independent intellectual property rights, actively carry out intellectual property protection and application, establish a comprehensive intellectual property management system and mechanism, and have comprehensive intellectual property strength. The evaluation process comprehensively evaluates the comprehensive intellectual property strength of enterprises from four dimensions: intellectual property creation, application, management, and protection. This selection is an affirmation of GeneCradle's R&D strength in the field of gene drug research and development by the National Intellectual Property Administration, and it also encourages the company to continue to use independent R&D and innovation capabilities as the core driving force for corporate development.
About GeneCradle
Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with AAV vector delivery technology-mediated gene therapy drug development as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.